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Thispaperaimedtoevaluatetheleptinroleonthecellularproliferationandtheexpressionofﬁbroblastgrowthfactor2,aromatase
enzyme, and apoptotic genes in the human prostate tissue. Methods. Fifteen samples of hyperplasic prostate tissue were divided
in four symmetric parts maintained in RPMI medium supplemented with 10% fetal bovine serum, 1ng/mL of gentamicin, and
added with 50ng/mL leptin (L) or not (C). After 3 hours of incubation, gene expression was evaluated by real time RT-PCR.
Cellular proliferation was evaluated by immunohistochemistry for PCNA. Results. The leptin treatment led to an increase cellular
proliferation (C = 21.8 ± 0.5; L = 64.8 ± 0.9; P<0.0001) and in the expression of Bax (C = 0.4 ± 0.1; L = 0.9 ± 0.2; P<0.05)
while Bcl-2 (C = 19.9±5.6; L = 5.6±1.8; P<0.05), Bcl-x (C = 0.2±0.06; L = 0.07±0.02; P<0.05), and aromatase expressions
(C = 1.9 ± 0.6; L = 0.4 ± 0.1; P<0.04) were signiﬁcantly reduced. Conclusion. Leptin has an important role in maintaining
the physiological growth of the prostate since it stimulates both cellular proliferation and apoptosis, with the decrement in the
aromatase gene expression.
1.Introduction
The prostate is a sexual accessory gland that produces
key substances for the eﬃcacy of sperm to fertilize eggs
within the female reproductive tract. Its secretion is a thin
milky ﬂuid that contains calcium, citrate ion, phosphate
ion, a clotting enzyme, and a proﬁbrinolysin. The slightly
alkaline characteristic of the prostatic ﬂuid may be quite
important for successful fertilization of the ovum [1].
After a physiological growth to adult size, the prostate
enters a maintenance phase, where prostatic cell prolif-
eration occurs at a daily rate of 1-2% and it is coun-
terbalanced by an equal rate of programmed cell death
[2, 3].
The prostate is an androgen-dependent organ, but
despite its action on the prostate, androgens can also be
converted into estrogens by the enzyme aromatase [4]. The
role of estrogen in the prostate is complex and particularly
dependent on local signaling mechanisms to maintain a
balance between the adverse and beneﬁcial eﬀects of this
hormone [5]. The prostate is also under inﬂuence of
adipokines such as leptin [6, 7]. There are six known splice
variants of the leptin receptor (ObRa to ObRf), all with the
same extracellular domain but with diﬀering intracellular
domains. Only the long isoform, ObRb, contains all intracel-
lular parts able to activate the signaling pathways expressed
mainly in the hypothalamus. Within the short isoforms,
ObRa is the most expressed in the peripheral tissues
[8].
The benign prostate hyperplasia (BPH) is the disease
in which the prostate shows an abnormal growth. The
prevalence of histologic marks of BPH is age related, rising
up to 88% in the ninth decade of life [9]. Nonetheless, the
etiology of BPH is far from being completely understood,
despite the great eﬀorts showed by molecular and clinical
studies. Most of these studies are focused on hormonal
factors, postulating that advanced age and the presence of
normal levels of serum testosterone were the two best-
established conditions for the development of BPH. Based
on the role played in several models of human pathology,
cellular proliferation and apoptosis have been investigated2 The Scientiﬁc World Journal
extensively in the last decade, achieving signiﬁcant improve-
ments in our knowledge of both physiologic prostate growth
and BPH pathogenesis.
Leptin, the most well-characterized adipokine involved
in reproduction, is known by its eﬀect in decreasing caloric
intake and increasing energy expenditure [10]. Besides
follicle stimulating and luteinizing hormones, leptin has an
important role regulating the reproductive system [10]. It
is also known that there is a link between obesity and BPH
[11]. Based on these facts, the aim of the present study was to
evaluate,usinghumanhyperplasicprostatetissue,howleptin
can regulate proliferation and the expression of ﬁbroblast
growth factor 2 (FGF2), aromatase enzyme, and apoptotic
genes.
2.MaterialandMethods
This project was approved by the ethical committee of the
Biology Institute of the State University of Rio de Janeiro.
Hyperplasic prostate tissue samples obtained by transvesical
prostatectomy in ﬁfteen patients with enlarged prostates that
caused mainly postvoiding residual urine and several LUT’s
symptoms were used. Patients presenting one or more of the
conditions below were excluded from the study: medication
use for LUT’S, abnormal glucose fasting, BMI above 25,
and recent urinary instrumentation. Those measures were
used to avoid bias, such as apoptosis induction, interactions
between insulin and leptin, inﬂammatory condition with
leptin increase in obese individuals, and urinary tract
infection, respectively. Other disturbances if under control
were accepted.
A transversal piece of each adenoma was taken under
sterile conditions, then immersed into the culture medium,
at 4◦C and sent to the lab immediately. Each sample was
divided in four symmetric parts which were maintained
in RPMI (Roswell Park Memorial Institute) medium sup-
plemented with 10% fetal bovine serum and 1ng/mL of
gentamicin. After one hour of incubation, the medium was
changed by the same medium as above supplemented (L)
or not (C) with 50ng/mL leptin. After 3 hours of incuba-
tion, RNA was extracted using Trizol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol
from one tissue piece of each group. Then 1µgR N A
sample was used in a 20µL cDNA reaction using oligo-dT
and the superscript III cDNA synthesis system (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol.
The gene expression of FGF2, aromatase, Bax, Bcl-x, and
Bcl-2 was evaluated by real time polymerase chain reaction
(primer sequences listed in Table 1). The sample was also
submitted to histopathology analysis to conﬁrm it as benign
hyperplasic tissue. The sequence of primers is listed on
Table 1.
Cellular proliferation was evaluated by immunohis-
tochemistry in the other tissue sample of each group.
Five deparaﬃniled tissue sample sections in each group
were hydrated, treated with buﬀer TRIS-EDTA (pH 9.0)
overnight at 60◦C for antigen retrieval, and then treated
with 3% hydrogen peroxide solution in methanol for
Table 1: Sequence of primers.
Gene Sequence
Aromatase Forward primer gcttctcatcgcagagtatccgg
Reverse primer caagggtaaattcattgggcttgg
Bax Forward primer ggggacgaactggacagtaa
Reverse primer cagttgaagttgccgtcaga
Bcl-2 Forward primer atgtgtgtggagagcgtcaa
reverse primer acagttccacaaaggcatcc
Bcl-x Forward primer cgtagacaaggagatgcaggt
Reverse primer accagcggttgaagcgctcct
FGF-2 Forward primer ccgttacctggctatgaagg
Reverse primer actgcccagttcgtttcagt
GAPDH Forward primer tcgtggaaggactcatgac
Reverse primer ccatcacgccacagttt
10min to block endogenous peroxidase activity. These
steps were followed by washing the sections in PBS and
subsequently incubating for 10min at room temperature
with 10% goat serum to block unspeciﬁc binding. The
sections were then incubated for 2h at 37◦Cw i t hm o u s e
anti-PCNA (Proliferating Cell Nuclear Antigen; Invitrogen,
CA, USA, cat#180110), diluted 1:200 in PBS with 1%
BSA. Sections were then washed in PBS and incubated at
room temperature for 20min with biotinylated secondary
antibody followed by incubation at room temperature for
10min with streptavidinperoxidase conjugate (Histostain-
PlusKit,Invitrogen,CA,USA).SectionswerewashedinPBS,
then revealed with liquid diaminobenzidine (Histostain-
Plus Kit, Invitrogen, CA, USA), and then counterstained
with hematoxylin. The negative controls were processed by
replacing the primary antibody with PBS and no indication
of staining was observed. Images were digitized using an
Olympus DP70 (12.5megapixels, Tokyo, Japan) video cam-
e r ac o u p l e dt oaB X 5 1O l y m p u sl i g h tm i c r o s c o p e( T o k y o ,
Japan).
The histomorphometric evaluation of cellular prolifera-
tion was performed in a ﬁnal increase of 600x and estimated
by the number of stained nuclei of epithelial and stromal
cells counted in a area of 0.04mm2 with a speciﬁc software
(Image J 1.41; NIH, Bethesda, USA).
Data were reported as mean ± SEM. Statistical sig-
niﬁcance of experimental observations was determined by
Student’s t test. The level of signiﬁcance was set at P ≤ 0.05.
3. Results
Figure 1 shows the apoptotic gene expression results eval-
uated by real-time PCR. The leptin treatment leads to a
signiﬁcant (P<0.05) increase in the expression of the pro
apoptotic gene Bax while the antiapoptotic genes Bcl-2 and
Bcl-x expressions were signiﬁcantly (P<0.05) reduced.
Comparing the expression of both antiapoptotic genes, Bcl-2
wasmoreexpressedinbothgroupsthanBcl-x.Thediﬀerence
w a sa b o u t2 0t i m e sm o r ei nCg r o u pa n d1 0t i m e sm o r ei nL
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Figure 1: Gene expression of Bax (a), Bcl-2 (b), and Bcl-x (c) in the human hyperplasic prostate tissue after leptin treatment, 50ng/mL,
(Leptin)ornot(Control)for3hours.GAPDHwasusedasaninternalcontrol.PrimersequencesarelistedintheTable 1.Dataarerepresented
as mean ± SEM of 15 individuals. Diﬀerent letters mean statistically signiﬁcance.
The expression of FGF2 and aromatase genes is shown
in Figure 2. While there was no signiﬁcant alteration in the
FGF2 expression, the aromatase expression was signiﬁcantly
(P<0.04) reduced by the leptin treatment.
The cellular proliferation was evaluated by PCNA im-
munohistochemistry. The leptin treatment resulted in a sig-
niﬁcant (P<0.0001) increase in the number of stained cells
(Figure 3). The immunohistochemistry photomicrograph is
shown in Figure 4.
4. Discussion
Leptin is one of the most important factors, besides follicle
stimulating and luteinizing hormones, in the regulation of
reproductivesystem[10].Asinothertissuesofthereproduc-
tive system, the prostate not only expresses leptin receptors
but also synthesizes the hormone itself [12, 13]. Leptin has
been associated with prostate diseases but the real role of this
hormone in the normal or abnormal prostate tissue has not
yet been clariﬁed.
Several papers show that there is a link between obesity
and prostate neoplasms, such as BPH and prostate cancer
[14, 15]. An increase in leptin expression in prostate tissue
is also related to the progression and the degree of malig-
nancy of PCa [16]. It has been reported that the blood
concentration of leptin, as well as the amount of leptin in the
tissue, is related to the progression of several cancers besides
the prostate [17, 18]. It is also known that leptin stimulates
cellular proliferation of benign prostatic hyperplasia. In spite
of those papers, we have no knowledge about the direct
eﬀects of leptin in the human prostate gland. So, we believe
that this is the ﬁrst time a direct eﬀect of leptin has been
shown in the human prostate using an in vitro culture tissue
assay.
The equilibrium between proliferation and apoptosis is
very important to maintain the physiological growth of the
adult prostate [2, 3]. Based on this statement, any factor that
alters that equilibrium could result in an abnormal growth
of the prostate. The fact that leptin treatment caused an
increase in the expression of the proapoptotic gene Bax and
a reduction in the expression of both antiapoptotic genes
Bcl-2 and Bcl-x suggests that one of the leptin functions in
the prostate is to favor the apoptosis reaction. Corroborating
the literature [19], our results also show that Bcl-2 is more
expressed than the other apoptotic genes. Leptin treatment
did not change that relation.4 The Scientiﬁc World Journal
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Figure 2:GeneexpressionofFGF2(a)andaromatase(b)inthehumanhyperplasicprostatetissueafterleptintreatment,50ng/mL,(Leptin)
or not (Control) for 3 hours. GAPDH was used as an internal control. Primer sequences are listed in the Table 1. Data are represented as
mean ± SEM of 15 individuals. Diﬀerent letters mean statistically signiﬁcance.
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Figure 3: Cellular proliferation evaluated by PCNA technique
throughimmunohistochemistry,inthehumanhyperplasicprostate
tissue after leptin treatment, 50ng/mL, (Leptin) or not (Control)
for 3 hours. Data are represented as mean ± SEM of 15 individuals.
Diﬀerent letters mean statistically signiﬁcance.
PCNA immunohistochemistry results showed that
leptin-stimulated proliferation in the prostate corroborating
a previous study that showed that leptin could stimulate
proliferation and migration in prostate cell lines [20]. The
combination of these results suggests that in the prostate,
leptin is important to maintain the normal physiological
adult growth balance by favoring both apoptosis and pro-
liferation reactions. These results are in agreement with the
leptin role in human ovarian cells where this hormone has
the ability to stimulate both proliferation and apoptosis [21].
The prostate is known to be strongly inﬂuenced by
androgens whose eﬀects are thought to be mediated by inter-
actions between epithelial and stromal compartments,
through a complex network of paracrine and autocrine fac-
tors. Basic ﬁbroblast growth factor was the ﬁrst growth
factor to be isolated in the prostate with mitogenic eﬀect on
epithelialorstromalcells[22].Diidrotestosteroneisthemost
potent androgen aﬀecting the prostate. It has an important
role on prostate growth modulation, since it inﬂuences the
(a)
(b)
Figure 4: Photomicrography showing immunohistochemistry of
PCNA, in the human hyperplasic prostate tissue after leptin treat-
ment, 50ng/mL, (Leptin) or not (Control) for 3 hours. Magniﬁca-
tion of 600x.
prostatic homeostasis, which is controlled by mitogenic and
inhibitor factors, responsible for cellular proliferation and
cell death, respectively [23]. As there was no change in the
FGF2 gene expression by the leptin treatment, we couldThe Scientiﬁc World Journal 5
hypothesize that this hormone has a local and direct eﬀect
upon proliferation that is not secondary to FGF.
Estrogen regulation has also been considered as one of
the hormonal risk factors in association with the develop-
ment of benign prostatic hyperplasia and prostate cancer
[24–26]. An increase in aromatase expression is shown in
several types of cancer including prostate [27]a n db r e a s t
cancer [28]. Leptin has been shown to increase aromatase
expression and activity in human-luteinized granulosa [29]
and MCF-7 cell line [30]. In this study, we observed that
leptin treatment led to a decrease in aromatase expression
suggesting that in the prostate leptin could have a protective
eﬀect against abnormal growth, especially considering the
proliferation and apoptosis eﬀects of the hormone.
It has been shown in a mouse model that the prostate
gland is dependent upon both androgenic and estrogenic
responses and none of these hormones alone is suﬃcient to
evoke aberrant patterns of growth, resulting in malignancy
[31].So,despitetheprotectiveeﬀectthatleptinseemstohave
in this in vitro model, we cannot forget that, in vivo, leptin
actions in the prostate gland probably are dependent on
other hormones. So, the lack of synergism among leptin and
others hormones in the in vitro system could be responsible
for the diﬀerence between in vivo and in vitro eﬀects of the
hormone.
5. Conclusion
We can conclude that in the human prostate leptin alone
seems to have an important role in maintaining the normal
physiological growth of the organ. This eﬀect could be
reached by the fact that leptin stimulates both cellular
proliferation and apoptosis along with the decrement in the
aromatase gene expression.
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